Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Company Overview

Eloxx Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on compounds intended to help cells produce functional proteins when a genetic mutation prematurely stops protein production.

The company’s lead investigational candidate, ELX-02, was designed to promote ribosomal readthrough of these premature stop signals. Eloxx studied the candidate for conditions including cystic fibrosis and nephropathic cystinosis in patients with relevant genetic mutations. ELX-02 was investigational and was not a marketed treatment.

In 2024, Eloxx completed a business combination with Zenas BioPharma, and the combined company began operating under the Zenas BioPharma name.

Key Stats

• Today's Range: $12.07 to $13.23
• 50-Day Range: $12.21 to $18.25
• 52-Week Range: $8.20 to $23.40
• Volume: 14,757 shs
• Average Volume: 25,654 shs
• Market Capitalization: $53.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.33
• Consensus Rating: Moderate Buy

Eloxx Pharmaceuticals Stock Analysis - MarketRank™

Eloxx Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 194th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eloxx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Eloxx Pharmaceuticals has a consensus price target of $37.33, representing about 183.9% upside from its current price of $13.15.

Amount of Analyst Coverage

Eloxx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($2.61) to ($2.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eloxx Pharmaceuticals is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eloxx Pharmaceuticals is -8.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.76% of the float of Eloxx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eloxx Pharmaceuticals has a short interest ratio ("days to cover") of 2.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eloxx Pharmaceuticals has recently increased by 27.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eloxx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eloxx Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.91

News Sentiment

Eloxx Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Eloxx Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ELOX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 11/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ELOX
• CIK: 1035354
• Web: www.eloxxpharma.com
• Phone: 781-577-5300
• Fax: 908-864-4440
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eloxx Pharmaceuticals: $37.33
• High Price Target: $40.00
• Low Price Target: $32.00
• Potential Upside/Downside: +183.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.74
• Quick Ratio: 3.74

Sales & Book Value

• Annual Sales: $6.36 million
• Price / Sales: 8.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($85.17) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 4,040,000
• Free Float: 2,991,000
• Market Cap: $53.13 million
• Optionable: N/A
• Beta: -1,918.69